The Xe MRI Clinical Trials Consortium (Xe MRI CTC) was established in 2015 and now consists of 13 Clinical Research Centers with established 129Xe in-vivo MRI capabilities and independent INDs (or equivalent) within North America and Europe. These sites are in Cincinnati, OH, Columbia, MO, Charlottesville, VA, Durham, NC, Hamilton, ON, Iowa City, IA, Kansas City, KS, London, ON, Sheffield, UK, Toronto, ON, Vancouver, BC, Hanover, Germany, and Aarhus, Denmark.

Consortium Overview

The purpose of this cooperative research consortium is to facilitate clinical research, education, and awareness of the capabilities of Xe MRI through support for:

1. Collaborative clinical research in both adult and pediatric lung diseases, including longitudinal studies of individuals with lung disease, cross sectional clinical studies, phase one, two, and three trials, and/or pilot and demonstration projects.

2. Training of scientific and clinical investigators in hyperpolarized gas research.

3. Providing a test bed for novel approaches and technologies for biomarkers and image guided interventions.

4. Offering a platform for sharing protocols, MRI sequences, and image analysis algorithms for the associated institutions. 

5. Developing and maintaining an international lung MRI database to serve as a centralized repository for shared imaging data, with the goal of enhancing standardization and harmonization across all Consortium sites.

6. Working collaboratively with private industry where appropriate to achieve scientific goals.

Each of the individual Clinical Research Centers is comprised of basic and clinical investigators, institutions, CTSAs, and relevant organizations, for the utilization of hyperpolarized gases in translational research.

• Identification of biomarkers for disease risk

• Mechanisms for monitoring disease severity/activity

• Development of image guided interventions

This cooperative program facilitates:

Upcoming Industry Events